Skip to content
stoqly

Natural Alternatives International Inc

NAII Nasdaq Medicinal Chemicals & Botanical Products Financials FY2017–FY2026

Revenue Total sales reported in the income statement.
$143M
9.7% vs prior year
Operating margin Operating income as a share of revenue.
βˆ’13.2%
6.5 pts
Net income Profit after all expenses, interest and tax.
βˆ’$20.7M
Free cash flow Cash from operations minus capital spending.
βˆ’$12.6M
644.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
β€”
Market cap Last close times the latest diluted share count, so it is approximate.
β€”
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$3.43 EPS (TTM)

What Natural Alternatives International Inc does

No business description yet.

Legal name
NATURAL ALTERNATIVES INTERNATIONAL INC
Fiscal year ends
June 30, 2026
Latest annual report
10-K Β· Sep 28, 2026
Accession Β· CIK
0001437749-26-031343
0000787253

Revenue and margins

Natural Alternatives International Inc had $143M of revenue in fiscal 2026, up 9.7% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was βˆ’$12.6M in fiscal 2026, βˆ’8.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Natural Alternatives International Inc returned $0.1M to shareholders in fiscal 2026. The diluted share count rose 1.4%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Natural Alternatives International Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $21.8M$13.6M$12.0M$12.3M$7.4M
Current ratio 3.2x3.6x2.6x2.1x1.7x
Quick ratio 1.9x1.7x1.6x1.2x0.9x
Total assets $146M$134M$162M$152M$126M
Total liabilities $57.5M$45.4M$79.7M$83.5M$76.5M
Shareholders' equity $88.5M$88.8M$82.6M$68.4M$50.0M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ• βœ• βœ•
Cash from operations is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ“ βœ•
Return on assets rose β€” βœ• βœ“ βœ• βœ“ βœ• βœ• βœ• βœ• βœ•
Cash from operations exceeds net income βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” βœ• βœ• β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ• βœ“ βœ• βœ“ βœ• βœ“ βœ• βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ• βœ•
Gross margin rose β€” βœ• βœ• βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ•
Revenue rose relative to assets β€” βœ• βœ• βœ• βœ“ βœ• βœ• βœ• βœ“ βœ“
F-score β€” / 32 / 95 / 93 / 88 / 85 / 85 / 82 / 84 / 82 / 8
Accruals ratio βˆ’9.5%4.1%βˆ’0.0%βˆ’5.0%βˆ’8.3%βˆ’0.9%βˆ’3.2%βˆ’3.9%βˆ’12.4%βˆ’8.5%
Altman Z'' 12.3010.8411.035.777.856.366.253.743.072.12

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $122M $132M $138M $119M $179M $171M $154M $114M $130M $143M
Net interest income βˆ’$0.0M βˆ’$0.0M βˆ’$0.0M βˆ’$0.1M βˆ’$0.1M βˆ’$0.1M βˆ’$0.5M βˆ’$0.4M βˆ’$0.9M βˆ’$1.2M
Gross profit $26.2M $26.3M $23.6M $18.9M $30.4M $30.5M $18.2M $6.9M $9.3M $9.0M
Research and development $1.6M $1.5M $1.8M $1.8M $1.9M $2.5M $2.1M $1.9M $1.8M $2.3M
Operating income $9.7M $9.5M $6.0M βˆ’$1.5M $13.7M $13.7M $4.7M βˆ’$8.5M βˆ’$8.7M βˆ’$18.8M
Pretax income $10.1M $10.6M $8.0M βˆ’$1.7M $12.1M $13.7M $3.6M βˆ’$9.5M βˆ’$10.7M βˆ’$20.3M
Income tax $2.9M $5.6M $1.4M βˆ’$0.1M $1.4M $2.9M $1.0M βˆ’$2.2M $2.8M $0.4M
Net income $7.2M $5.1M $6.5M βˆ’$1.6M $10.8M $10.7M $2.5M βˆ’$7.2M βˆ’$13.6M βˆ’$20.7M
Diluted EPS $1.09 $0.73 $0.92 βˆ’$0.25 $1.69 $1.74 $0.43 βˆ’$1.23 βˆ’$2.28 βˆ’$3.43
Diluted shares 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B 0.01B
Cash flow
Cash from operations $14.1M $1.8M $6.6M $3.7M $20.8M $11.9M $7.0M βˆ’$1.5M $5.9M βˆ’$8.9M
Capital expenditure $5.4M $4.1M $5.3M $4.5M $5.1M $26.5M $13.5M $3.0M $3.6M $3.7M
Free cash flow $8.8M βˆ’$2.2M $1.2M βˆ’$0.9M $15.7M βˆ’$14.6M βˆ’$6.5M βˆ’$4.5M $2.3M βˆ’$12.6M
Depreciation and amortization $2.4M $2.9M $3.5M $4.0M $4.3M $4.2M $4.3M $4.6M $4.6M $4.7M
Stock-based compensation $1.0M $1.3M $1.7M $1.7M $1.4M $1.0M $1.0M $1.2M $1.0M $0.6M
Share buybacks $0.7M $0.5M $1.4M $3.7M $4.1M $5.5M $1.5M $0.2M $0.2M $0.1M
Dividends and buybacks $0.7M $0.5M $1.4M $3.7M $4.1M $5.5M $1.5M $0.2M $0.2M $0.1M
Balance sheet
Cash and short-term investments $27.8M $23.6M $25.0M $30.5M $32.1M $21.8M $13.6M $12.0M $12.3M $7.4M
Total debt $0.0M $0.0M $0.0M β€” β€” β€” β€” β€” β€” β€”
Current assets $51.7M $65.2M $71.4M $79.0M $80.3M $76.7M $57.0M $61.6M $59.3M $65.4M
Current liabilities $10.3M $14.3M $14.3M $27.8M $22.1M $23.9M $15.9M $23.5M $28.8M $37.7M
Inventory $13.7M $23.6M $26.0M $28.0M $27.0M $32.5M $29.7M $24.2M $24.9M $30.8M
Property and equipment, net $18.1M $19.3M $21.1M $21.5M $22.3M $44.6M $53.8M $52.2M $50.9M $35.6M
Total assets $72.6M $85.2M $93.5M $120M $120M $146M $134M $162M $152M $126M
Total liabilities $11.5M $17.0M $17.4M $48.8M $40.2M $57.5M $45.4M $79.7M $83.5M $76.5M
Preferred stock $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $61.1M $68.2M $76.1M $71.4M $80.1M $88.5M $88.8M $82.6M $68.4M $50.0M
Margins
Gross margin 21.5% 19.9% 17.0% 15.9% 17.1% 17.8% 11.8% 6.0% 7.2% 6.3%
Operating margin 8.0% 7.2% 4.3% βˆ’1.3% 7.7% 8.0% 3.1% βˆ’7.5% βˆ’6.7% βˆ’13.2%
EBITDA margin 9.9% 9.4% 6.8% 2.1% 10.1% 10.4% 5.8% βˆ’3.4% βˆ’3.2% βˆ’9.9%
Net margin 5.9% 3.8% 4.7% βˆ’1.4% 6.0% 6.3% 1.6% βˆ’6.3% βˆ’10.5% βˆ’14.5%
FCF margin 7.2% βˆ’1.7% 0.9% βˆ’0.7% 8.8% βˆ’8.6% βˆ’4.2% βˆ’4.0% 1.8% βˆ’8.9%
Net interest share of revenue βˆ’0.0% βˆ’0.0% βˆ’0.0% βˆ’0.1% βˆ’0.1% βˆ’0.0% βˆ’0.3% βˆ’0.3% βˆ’0.7% βˆ’0.8%
Returns
Return on capital 20.8% 13.9% 9.6% β€” β€” β€” β€” β€” β€” β€”
Return on capital employed 15.6% 13.4% 7.5% βˆ’1.6% 13.9% 11.2% 4.0% βˆ’6.1% βˆ’7.0% βˆ’21.1%
Return on equity 11.8% 7.8% 9.1% βˆ’2.2% 14.2% 12.7% 2.8% βˆ’8.4% βˆ’18.0% βˆ’35.0%
Return on assets 10.0% 6.4% 7.3% βˆ’1.5% 9.0% 8.0% 1.8% βˆ’4.9% βˆ’8.6% βˆ’14.9%
Return on tangible equity 11.8% 7.4% 8.6% βˆ’2.3% 13.4% 12.1% 2.8% βˆ’8.7% βˆ’19.8% βˆ’41.4%
Growth
Revenue growth β€” 8.6% 4.4% βˆ’14.0% 50.2% βˆ’4.2% βˆ’9.9% βˆ’26.1% 14.1% 9.7%
Net income growth β€” βˆ’30.2% 29.5% βˆ’125.1% β€” βˆ’0.5% βˆ’76.5% βˆ’386.2% β€” β€”
EPS growth β€” βˆ’33.0% 26.0% βˆ’127.2% β€” 3.0% βˆ’75.3% βˆ’386.0% β€” β€”
FCF growth β€” βˆ’125.6% β€” βˆ’168.7% β€” βˆ’193.1% β€” β€” β€” βˆ’644.3%
Share count change β€” 3.5% 3.1% βˆ’5.7% βˆ’4.7% βˆ’3.5% βˆ’4.5% βˆ’0.1% 1.3% 1.4%
Financial health
Net debt / EBITDA βˆ’2.3x βˆ’1.9x βˆ’2.7x β€” β€” β€” β€” β€” β€” β€”
Debt / equity 0.0x 0.0x 0.0x β€” β€” β€” β€” β€” β€” β€”
Current ratio 5.0x 4.6x 5.0x 2.8x 3.6x 3.2x 3.6x 2.6x 2.1x 1.7x
Quick ratio 3.7x 2.9x 3.2x 1.8x 2.4x 1.9x 1.7x 1.6x 1.2x 0.9x
Capital allocation
Capex / revenue 4.4% 3.1% 3.9% 3.8% 2.9% 15.5% 8.8% 2.7% 2.8% 2.6%
Stock comp / revenue 0.8% 1.0% 1.2% 1.4% 0.8% 0.6% 0.7% 1.1% 0.8% 0.4%
Payouts / FCF 8.1% β€” 110.5% β€” 26.4% β€” β€” β€” 7.7% β€”
Quality scores
Piotroski F-score β€” 2.0 5.0 3.0 8.0 5.0 5.0 2.0 4.0 2.0
Altman Z'' 12.3 10.8 11.0 5.8 7.8 6.4 6.2 3.7 3.1 2.1
Accruals ratio βˆ’9.5% 4.1% βˆ’0.0% βˆ’5.0% βˆ’8.3% βˆ’0.9% βˆ’3.2% βˆ’3.9% βˆ’12.4% βˆ’8.5%

Source: SEC EDGAR XBRL filings (CIK 0000787253). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open